Saito, Yoshimasa

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 薬物治療学講座 ( Shiba-Kyoritsu )

Position

Professor
Scopus Paper Info  
Paper Count: 108 Citation Count: 6619 h-index: 41

Click to view the Scopus page. The data was downloaded from Scopus API in March 29, 2026, via http://api.elsevier.com and http://www.scopus.com .

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Tumor diagnostics and therapeutics

Page Top ▲
 

Books 【 Display / hide 】

  • Genes and Antiaging Medicine: Epigenetics and Antiaging

    Saito Y., Anti Aging Medicine Basics and Clinical Practice, 2025.01

    　View Summary

    Epigenetics refers to the chemical modifications to DNA and histones that control gene expression without changing the DNA base sequence, and these changes are usually inherited after cell division. Typical examples of epigenetic changes include DNA methylation and acetylation and methylation of histones. Also, while the general term for the information of the DNA base sequence is called the “genome,” the general term for the epigenetic information that modifies this genome is called the “epigenome.” DNA methylation is the only physiological modification in the genome of vertebrates. DNA methylation is a reaction in which a methyl group is added to the 5-position carbon atom of cytosine (C) in a 2-base sequence (CpG) arranged from the 5′ side of DNA in the order of cytosine (C), guanine (G), and is catalyzed by DNA methyltransferase (DNMT). Many gene promoter regions have clusters of CpG sequences called CpG islands (Fig. 18.1). In the promoter regions of genes that generally show active expression, DNA methylation is not observed, and histones are acetylated. On the other hand, when the ninth lysine residue (H3K9) of histone H3 is methylated, it recruits DNMT and histone deacetylase (HDAC), DNA is methylated, and histones are deacetylated. These modifications cause the chromatin structure to aggregate and gene expression to be inactivated (Fig. 18.1). Thus, changes in the epigenome play a role like a switch that controls the ON and OFF of gene expression.

  • 遺伝子診断と個別化医療.「ゲノム創薬科学」

    Saito Yoshimasa, 裳華房, 2017.10

    Scope: pp269-287

  • エピジェネティクスとアンチエイジング医学.「アンチエイジング医学の基礎と臨床」第3版.

    齋藤 義正, メジカルビュー社, 東京, 2015.09

    Scope: pp42-44

  • Advanced Glycation End-products (AGEs)阻害薬がOLEFTラットの肝および脂肪組織に及ぼす影響. 「酸化ストレスと肝疾患 8巻」.

    木村真規、南雲まい、飯田陽子、山田華名、齋藤義正、齋藤英胤., 株式会社嵯峨野, 東京, 2012.09

    Scope: pp67-72

  • 加齢と消化器系の変化.「高齢者用食品の開発と展望」.

    齋藤義正、齋藤英胤., シーエムシー出版, 東京, 2012.07

    Scope: pp7-12

Page Top ▲

Papers 【 Display / hide 】

  • Analysis of miRNA Expression Changes Induced by Kras<SUP>G12D</SUP> Mutant Cells in Pancreatic Ductal Progenitor Cells

    Ohshima, Y; Matsuzaki, J; Oikawa, C; Shibagaki, R; Koreeda, T; Ochiya, T; Katsuda, T; Saito, Y

    CANCER SCIENCE 117   1732 - 1732 2026.01

    ISSN  1347-9032

  • Third-Line and Later Susceptibility-Guided Helicobacter pylori Eradication Therapies: A Multicenter Study of Vonoprazan–Amoxicillin–Sitafloxacin/Rifabutin Regimens

    Mori H., Saito Y., Ando H., Masaoka T., Matsuzaki J., Nakano M., Kanai T.

    Journal of Clinical Medicine 15 ( 2 )  2026.01

    　View Summary

    Background/Objectives: Although vonoprazan-based triple therapy has improved the first- and second-line Helicobacter pylori eradication rates, a subset of patients still require third-line or later treatments. The present study aimed to evaluate the efficacy and safety of susceptibility-guided eradication strategies from third-line or later treatments in a multicenter setting. Methods: This retrospective multicenter study (2019–2024) enrolled 94 patients who had failed second-line eradication therapy and underwent H. pylori isolation and susceptibility testing. Based on sitafloxacin sensitivity, patients received vonoprazan, amoxicillin, and sitafloxacin (VAS) if sensitive, or vonoprazan, amoxicillin, and rifabutin (VAR) if resistant. Altogether, 75 patients received treatment according to this protocol. Results: Among the 75 patients, 61.3% were sitafloxacin-sensitive (VAS group), and 38.7% were resistant (VAR group). All strains were rifabutin-sensitive. The overall eradication rates were 92.0% and 95.8% in the intention-to-treat and per-protocol analyses, respectively. Adverse events occurred in 17.3% of cases. One patient in the VAR group discontinued therapy due to dizziness, whereas all other adverse events were mild and did not require treatment cessation. Subgroup analysis showed eradication rates of 93.5% (43/46) and 89.7% (26/29) for the VAS and VAR groups, respectively. The eradication rate for third-line therapy was 96.2% (50/52), whereas that for fourth-line therapy was 85.7% (18/21). Fifth-line therapy showed an eradication rate of 50.0% (1/2). Conclusions: Susceptibility-guided vonoprazan-based regimens from the third-line treatment onward achieved high eradication and tolerability in a multicenter cohort. This approach may offer a valuable treatment option for patients with refractory H. pylori infections.

  • Study on the Impact of Co-mutations on Survival in Patients with Biliary Tract Cancer using real-world data in Japan

    Matsui, Y; Ida, K; Urabe, Y; Muramatsu, T; Matsuzaki, J; Saito, Y

    CANCER SCIENCE 117   719 - 719 2026.01

    ISSN  1347-9032

  • Impact of tsRNA derived from <i>Klebsiella pneumoniae</i> on hepatocarcinogenesis

    Oshima, K; Matsuzaki, J; Nakayama, J; Yamamoto, Y; Tsugawa, H; Kato, K; Ochiya, T; Saito, Y

    CANCER SCIENCE 117   199 - 199 2026.01

    ISSN  1347-9032

  • Exploring miRNAs Contributing to Resistance against Anti-CD40 Agonist Antibody Therapy in Mouse Pancreatic Cancer Cells

    Asakawa, Y; Matsuzaki, J; Koreeda, T; Shibagaki, R; Tan, YZ; Oshima, K; Oikawa, C; Nakamura, M; Imamoto, K; Saito, Y

    CANCER SCIENCE 117   54 - 54 2026.01

    ISSN  1347-9032

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • がんオルガノイドー創薬・個別化医療の革新的プレクリニカルモデルとして

    齋藤義正

    医学のあゆみ 286 ( 7, 8 ) 623 2023.08

    Article, review, commentary, editorial, etc. (scientific journal), Single Work

  • 胆道・膵臓がんオルガノイドを用いた個別化医療の実現に向けて

    齋藤義正

    医学のあゆみ 286 ( 7, 8 ) 649 - 652 2023.08

    Article, review, commentary, editorial, etc. (scientific journal), Single Work

  • 腸管上皮オルガノイドを用いたステムセルエイジング研究

    齋藤義正

    ファルマシア 56 ( 11 ) 994 - 998 2020.11

    Article, review, commentary, editorial, etc. (scientific journal), Single Work

  • Publisher Correction: Epigenetic silencing of Lgr5 induces senescence of intestinal epithelial organoids during the process of aging (npj Aging and Mechanisms of Disease, (2018), 4, 1, (12), 10.1038/s41514-018-0031-5)

    Uchida R., Saito Y., Nogami K., Kajiyama Y., Suzuki Y., Kawase Y., Nakaoka T., Muramatsu T., Kimura M., Saito H.

    npj Aging and Mechanisms of Disease (npj Aging and Mechanisms of Disease)  5 ( 1 )  2019.12

    　View Summary

    © 2019, The Author(s). The original version of this Article had an incorrect Article number of 1, an incorrect Volume of 5 and an incorrect Publication year of 2019. These errors have now been corrected in the PDF and HTML versions of the Article.

  • ヘリコバクター・ピロリ感染症とmicroRNA発現異常.

    齋藤義正, 鈴木秀和, 齋藤英胤.

    細胞 (ニューサイエンス社)  44(10)   6-9 2012.09

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

Page Top ▲

Presentations 【 Display / hide 】

  • 腸管上皮オルガノイドを用いたシングルセル解析により見えてきたこと

    齋藤義正

    [Domestic presentation]  日本生理学会 第100回記念大会, 

    2023.03
    , 

    Oral presentation (invited, special)

  • 誘導性CRISPR/dCas9を用いたC19MCの肝内胆管癌オルガノイドの分化における役割の解明

    葉 子祥、松崎 潤太郎、及川 千尋、金井 弥栄、齋藤 義正

    [Domestic presentation]  第81回 日本癌学会学術総会, 

    2022.09
    -
    2022.10
    , 

    Oral presentation (general)

  • 膵がんドライバー遺伝子変異誘導による形質変化の追跡

    及川 千尋、松崎 潤太郎、落谷 孝広、齋藤 義正

    [Domestic presentation]  第81回 日本癌学会学術総会, 

    2022.09
    -
    2022.10
    , 

    Oral presentation (general)

  • 難治性がんオルガノイドを用いた個別化医療の開発

    齋藤義正

    [Domestic presentation]  第4回Cell Based Assay Workshop, 

    2022.03
    , 

    Oral presentation (invited, special)

  • 胆道がん患者由来オルガノイドの樹立と創薬研究への応用

    齋藤義正

    [Domestic presentation]  患者由来がんモデル研究会2021, 

    2021.12
    , 

    Oral presentation (invited, special)

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • 国際協力による難治性がんオルガノイドライブラリーの構築

    2024.09
    -
    2027.03

    国際共同研究加速基金（海外連携研究）, Principal investigator

  • デザイナーエクソソームとオルガノイドを用いた個別化がん免疫療法の開発

    2024.06
    -
    2026.03

    挑戦的研究（萌芽）, Principal investigator

  • 胆道がん腫瘍微小環境の再構築による次世代オルガノイドの開発

    2024.04
    -
    2027.03

    基盤研究(B), Principal investigator

  • 抗真菌薬を基盤とした胆道・膵臓がんに対する新規治療薬の創製

    2020.04
    -
    2023.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Principal investigator

  • NAD+およびエピゲノムの制御による老化メカニズムの解明と新たな抗加齢介入の開発

    2019.06
    -
    2021.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Challenging Research (Exploratory) , Principal investigator

display all >>

Page Top ▲

Intellectual Property Rights, etc. 【 Display / hide 】

  • がん幹細胞集団の調製方法、異種移植片の調製方法、スクリーニング方法、ｍｉＲ－３４ａの発現量を低下させる方法及びがん幹細胞増殖抑制剤

    Date applied： 特願2015-142164  2015.07 

    Patent, Joint

Page Top ▲

Awards 【 Display / hide 】

  • Asian Pacific Digestive Week 2018, Emerging Leader Lectureship

    2018.11

    Type of Award： Award from international society, conference, symposium, etc.

  • 第18回日本抗加齢医学会総会　最優秀演題賞

    齋藤義正, 2018.05, 腸管上皮オルガノイドを用いたステムセルエイジングの検討

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 日本抗加齢医学会優秀演題賞　

    木村真規、井手晴香、白井栄里奈、内田諒英、齋藤義正、齋藤英胤.　, 2016.06, 第16回 日本抗加齢医学会総会, 高脂肪食摂取時の脂肪組織における老化マーカー遺伝子の発現変化とDNAメチル化阻害薬の効果.　

    Type of Award： Award from Japanese society, conference, symposium, etc.

    　View Description

    プログラム・抄録集: 170, 2016/6/10/12.

  • 日本抗加齢医学会優秀演題賞　

    内田諒英、齋藤義正、中岡哉彰、村松俊英、木村真規、齋藤英胤.　, 2016.06, 第16回 日本抗加齢医学会総会　プログラム・抄録集: 174, 2016/6/10/12., オルガノイド培養法により樹立した腸管上上皮幹細胞における stem cell aging の検討.　

    　View Description

    プログラム・抄録集: 174, 2016/6/10/12.

  • 慶應義塾大学薬学部学部長賞

    2015

    Type of Award： Keio commendation etc.

display all >>

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • DOCTORAL LECTURE ON CLINICAL PHARMACY 1

    2025

  • DISEASES AND PHARMACOTHERAPY 6 (RENAL, ENDOCRINE AND NERVOUS SYTEMS)

    2025

  • DISEASES AND PHARMACOTHERAPY 5 (GASTROINTESTINAL SYSTEM)

    2025

  • CLINICAL PHARMACOLOGY

    2025

  • CLINICAL EXPERIENCE PROGRAM

    2025

display all >>

Page Top ▲